XDx Gets CTAF Recommendation for AlloMap Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that the California Technology Assessment Forum has recommended the use of its AlloMap gene expression test.

The Brisbane, Calif.-based firm said that CTAF, which is a non-profit entity sponsored by Blue Shield of California to assess new and emerging medical technology, agreed that AlloMap met all five technology assessment criteria for safety, effectiveness, and improvement in health outcomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.